245 related articles for article (PubMed ID: 24936872)
1. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.
Jin J; Hu C; Yu M; Chen F; Ye L; Yin X; Zhuang Z; Tong H
PLoS One; 2014; 9(6):e100206. PubMed ID: 24936872
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].
Tong HY; Hu C; Yu MX; Ma QL; Chen FF; Ye L; Wei JY; Xu GX; Mao LP; Li Y; Jin J
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3180-4. PubMed ID: 24405536
[TBL] [Abstract][Full Text] [Related]
3. IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.
Wang N; Wang F; Shan N; Sui X; Xu H
Acta Haematol; 2017; 138(3):143-151. PubMed ID: 28873367
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
Lin P; Luo Y; Zhu S; Maggio D; Yang H; Hu C; Wang J; Zhang H; Ren Y; Zhou X; Mei C; Ma L; Xu W; Ye L; Zhuang Z; Jin J; Tong H
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1037-1047. PubMed ID: 29549529
[TBL] [Abstract][Full Text] [Related]
5. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Liu CY; Chen CY; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Feb; 89(2):137-44. PubMed ID: 24115220
[TBL] [Abstract][Full Text] [Related]
6. Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes.
Wu A; Gao P; Wu N; Shi C; Huang Z; Rong C; Sun Y; Sheng L; Ouyang G; Mu Q
BMC Cancer; 2021 May; 21(1):546. PubMed ID: 33985456
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
8. Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Chotirat S; Thongnoppakhun W; Wanachiwanawin W; Auewarakul CU
Blood Cells Mol Dis; 2015 Mar; 54(3):286-91. PubMed ID: 25486927
[TBL] [Abstract][Full Text] [Related]
9. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.
Patnaik MM; Hanson CA; Hodnefield JM; Lasho TL; Finke CM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
Leukemia; 2012 Jan; 26(1):101-5. PubMed ID: 22033490
[TBL] [Abstract][Full Text] [Related]
10. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
[TBL] [Abstract][Full Text] [Related]
11. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
Ann Hematol; 2012 Apr; 91(4):519-25. PubMed ID: 21997850
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis.
Zheng X; Zhan Z; Naren D; Li J; Yan T; Gong Y
PLoS One; 2017; 12(9):e0185053. PubMed ID: 28953917
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes.
Yan X; Wang L; Jiang L; Luo Y; Lin P; Yang W; Ren Y; Ma L; Zhou X; Mei C; Ye L; Xu G; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Med; 2021 Mar; 10(5):1759-1771. PubMed ID: 33609081
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of
Liang S; Zhou X; Pan H; Yang Y; Shi L; Wang L
Hematology; 2019 Dec; 24(1):613-622. PubMed ID: 31482762
[No Abstract] [Full Text] [Related]
15. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
[No Abstract] [Full Text] [Related]
16. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
Lin Y; Zheng Y; Wang ZC; Wang SY
Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
Hattakitpanitchakul S; Kobbuaklee S; Wudhikarn K; Polprasert C
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4037-4042. PubMed ID: 34967586
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
Wang RX; Wu DP; Chen SN; He J; Xu Y; Wang XL; Yin J; Tian H; Tian XP; Sun AN
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):751-5. PubMed ID: 23755812
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Chen JR; Yao Y; Xu HZ; Qin ZY
Medicine (Baltimore); 2016 Mar; 95(9):e2583. PubMed ID: 26945349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
